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ABSTRACT :
Miller Fisher Syndrome (MFS) is a rare variant of Guillain-Barré syndrome (GBS) which is an idiopathic
neuromuscular paralysis. It is considered as autoimmune disease because there are antibodies which attack the
nerve cell ﬁbers resulting in paralysis of muscles. This disease exhibits a classic clinical triad of ataxia,areﬂexia, and
ophthalmoplegiawhereas it could have more neurological symptoms.Basically it is diagnosed clinically but have a
serological test for its conﬁrmation i.e. anti-GQ1b antibody levels.Here, we report a stereotypical case of MFS with all
of its cardinal symptoms with addition of some other symptoms like diplopia, ptosis of an eye and unilateral facial
nerve palsy. This patient presented with all of these signs and symptoms preceded by an upper respiratory tract
illness. The suspected diagnosis was aided with itsserological marker anti-GQ1b antibody levels and nerve
conduction studies(NCS)/electromyographic(EMG)studies and the patient was successfully treated with multiple
sessions of plasmapheresis and reduction in severity of the disease was noticed.
KEYWORDS:
Miller Fisher Syndrome(MFS), Guillain-Barré syndrome(GBS),anti-GQ1b ganglioside antibodies(anti-GQ1b
antibody), Upper respiratory tract illness(URTI),nerve conduction studies(NCS).
INTRODUCTION:

These symptomswere progressive in nature &
were accelerating each day. All this started after
an upper respiratory tract illness which was
almost 10-12 days prior to the onset of these
presenting complains. The symptoms were
vague at the beginning but with time they were
becoming more prominent in nature
andparesthesias in both upper limbs alongwith an
opthalmoplegia had developed in the next few
days. She had no signiﬁcant past medical and
surgical history. She did not complain of any
bowel or urinary incontinence. Her personal
history was normal with good appetite and did not
have any smoking or alcohol intake history. In her
family none was diagnosed and treated for any
neurological diseases. She denied of taking any
allopathic and herbal medicine except for
herURTI (ﬂuoroquinolones) in the recent past.
On physical examination her vitals were in normal
range and she was oriented in time place and
person. Her facial examination revealed that
there was ptosis in left eye, could not look up and
was unable to show teeth especially, left side of
face. Later on in the next 1-2 day, she also had

In 1932, James Collier was the ﬁrst person to
acknowledge this disease but later on it was
named after Charles Miller Fisher(Canadian
1
neurologist) who reported 3 cases in 1956 . This
rare variant of GBS, is only noticed in about 1-5%
of all cases of GBS in Western regions of world2.
MFS symptoms usually begins within 1-2 weeks
after a respiratory infection similarly to GBS with
rapid evolution of its cardinal triadi.e.ataxia, are
ﬂexia, and ophthalmoplegia. The pivotal
dissimilarity between MFS and other common
variants of GBS is that the cranial nerves are
affected ﬁrst resulting in weakness of muscles
within or surrounding the eye with poor balance
&clumsy swaying walk. While, paralysis in other
2-3
forms of GBS typically initiate in the legs . Here,
we discuss a case of young woman with likely
MFS mingling with some my as the niagraves'
presentation symptoms.
CASE REPORT:
A 38 years old female, married and working as a
teacher presented to us with complains of double
vision, drooping of left eyelid & difﬁculty in walking
for the last 2 weeks.
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deviation of angle of mouth (left sided).Eye
examination revealed paralysis of various ocular
movements in both eyes and hadonly upward and
medial gazes (suggestive of 3, 4, 6 nerve palsy). The
pupils were round & small. Pupillary reﬂex was normal
in right eye but was sluggish in left eye with a mildly
dilated pupil. On oral examination sense of taste and
bulk of tongue was good but she was having mild
difﬁculty in swallowing various edibles. Furthermore,
palatal palsy and nasal twang to voice was also
observed.There was mild sensory loss in both hands,
arms and all motor reﬂexes were absent in upper
limbs. The reﬂexes were normal in lower limbs but heel
shin test was mildly impaired. The plantar reﬂex was
noted ﬂexor in both feet & showed no other focal
sensory/motor deﬁcits.The gait was ataxic & waddling
in nature.
Her lab investigations revealed
leucocytosis(67.2%neutrophils)& thrombocytosis in
complete blood picture. The whole metabolic panel
were innormal range(RFTs,LFTS,RBS).Moreover,
electrocardiogram was normal and urinalysis showed
no abnormalities.MRIbrainwas advised and results
cameabsolutely unequivocal with mild cerebral
atrophy and mild bilateral maxillary &ethmiodal
sinusitisexculding completely the Multiple sclerosis. To
exclude other neuromuscular diseases, such as
muscular dystrophy, Myasthenia Gravis, nerve
problems in the spine such as herniated disc &
peripheral nerve problems in arms & legs
electromyography (EMG)/NCS was done and it
showed abnormal studies. In the present clinical
scenario the EMG studies declared presence of small
sensory amplitude in upper limb nerves (bilateral). To
conﬁrm this suspected diagnosis anti-GQ1b antibody
levels were sent and came backnegative. It will be
present in most of the affected individuals but more
than 10% patients will have seronegative results.7-8,10
Then a central venous catheter was inserted infemoral
vein of the patient. A total of 5 sessions of
plasmapheresis were done on alternate days and her
symptoms started improving after the second session.
Physiotherapist was also involved and worked with
patient on daily basis. She was discharged from
hospital on 11thday of admission when she showed
major positive development in her symptoms. The
opthalmoplegia& gait was much improved as now she
can move without support but still had a clumsy gait.
She was asked for Outpatient follow-up after 2 weeks
of discharge.

MFS usually presents with its cardinal triad of
signs/symptoms(opthalmoplegia, ataxia, areﬂexia).
The less frequent complains associated with MFS are
urinary disturbances, facial and pupillary
palsies,dysesthesias of limbsand mild motor
weaknesses2. URTI is the most common preceded
event in majority of the cases of GBS and MFS (5676%). Moreover, the frequently involvedpathogens for
this ailment are Campylobacter jejuni and
Haemophilus inﬂuenzae8-9.
Mostly, opthalmoplegia is the ﬁrst presenting symptom
in a patient and it can be easily differentiated from other
chronic diseases like myasthenia gravis andmyotonic
dystrophybecause of its early onset of symptoms. The
body weakness in MFS shows a descending pattern
when compared to GBS (ascending paralysis) and
along with eye problems(opthalmoplegia,diplopia)
which is also very uncommon in it2,5. Areﬂexia, can be
present in several other conditions like metabolic
abnormalities(hypomagnesemia, use of medication
like antidepressants), diabetes, vitamin b12 deﬁciency
and lower motor neuron diseases. In our patient there
was no history of any chronic disease, trauma or any
use of drugs and all lab investigations were within
normal limits except of mild leucocytosis and
thrombocytosis.
Heavy metal work up was not needed ﬁrstly, as patient
is a teacher so exposure to any heavy metals is very
less likely(also gave no history)& secondly
opthalmoplegia is not present in metal poisonings only
peripheral neuropathies occurs mostly in it.
Multiple sclerosis was the ﬁrst thing to be ruled out as
MRI brain was absolutely normal (following the
McDonald's criteria) thus omitting the need of lumbar
puncture for oligoclonal bands in CSF.
A diagnosis of MFS can be made with proper history,
clinical examination, focusing on the triad of
symptoms, with normal metabolic panel and
inconclusive or normal studies of CT/MRI. EMG should
be done to differentiate it from myasthenia gravis. The
anti-GQ1b ganglioside antibodies level is the most
sensitive serological test and it can be raised in 90% of
the patients having MFS and completely negative in
normal population3. This antibody level is not speciﬁc
for MFS but it could be present in “anti-GQ1b
antibody syndrome” known for both central and
peripheral nervous system deﬁcits.
Treatment for MFS is same as it is for GBS i.e. IVIG or
plasmapheresis. Our patient had 5 sessions of
plasmapheresis on alternate days after which her
symptoms were resolved to almost 50% of the
presenting ones(opthalmoplegia& gait much
improved).
Ataxia or wobbly gait and opthalmoplegia mostly
resolve within 1-3 months of time period but complete
recovery is forecasted within 6 months2. Complications
are rare but it could result in respiratory failure or
cardiac arrhythmias or cardio pulmonary arrest6.

DISCUSSION:
Miller Fisher Syndrome(MFS) is a rare disease
accounting more in male population than women by a
ratio of approximately 2:13. It is documented in wide
range of ages but more commonly found in between 13
& 78 years2.
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CONCLUSION:
Although, it is very uncommon disease but it carries a
signiﬁcant place in the list of differential diagnosis of
ataxia &opthalmoplegia. This disease should be kept
in mind of a clinician because the vague presentation
of it makes difﬁcult to diagnose or can be confused with
other diseases.Thus, theprognosis of MFS is very
good irrespective of severity of symptoms and patients
return to their normal life by 6th month of the onset of
disease2.
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